Concepedia

Author

M. Frénay

Centre Antoine Lacassagne

Also Known As

Frenay, M., M Frenay, M. Frenay, M. Frénay, Marc Frenay, Mike Pezold

57

Publications

3.3K

Citations

20

H-Index

60

Concepts

All Affiliations

Centre Antoine LacassagneSorbonne UniversitéPitié-Salpêtrière HospitalHôpital PasteurCentre Hospitalier Régional et Universitaire de Nancy
MF

About

M. Frénay is an author at Centre Antoine Lacassagne specializing in medicine, oncology, and neuro-oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

15

568

2

Health Sciences

5

5

106

3

Engineering

2

2

97

4

Biomedical Engineering

2

2

97

5

Public Health

1

1

13

M. Frénay

×

26

Publications

3.2K

Citations

20

H-Index

YearCitations

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

Martin J. van den Bent, Alba A. Brandes, R. Rampling,

Journal of Clinical Oncology

2009

561

Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force

Riccardo Soffietti, Brigitta G. Baumert, Lorenzo Bello,

European Journal of Neurology

2010

499

Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases

Laurent Capelle, Denys Fontaine, Emmanuel Mandonnet,

Journal of neurosurgery

2013

409

Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971

Martin J. van den Bent, Alba A. Brandes, Johan Menten,

Journal of Clinical Oncology

2003

295

Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group

Khê Hoang‐Xuan, Luc Taillandier, Olivier Chinot,

Journal of Clinical Oncology

2003

262

Influence of sex and age on fluorouracil clearance.

G. Milano, M C Etienne, E. Cassuto‐Viguier,

Journal of Clinical Oncology

1992

256

Pregnancy increases the growth rates of world health organization grade II gliomas

Johan Pallud, Emmanuel Mandonnet, Christophe Deroulers,

Annals of Neurology

2009

106

Long-term outcome of oligodendrogliomas

Denys Fontaine, A. Ramaioli, Fanny Burel‐Vandenbos,

Neurology

2004

96

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF

Bruno Chauffert, L. Feuvret, Franck Bonnetain,

Annals of Oncology

2014

94

Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas

V. H.J.M. Triebels, Martin Taphoorn, Alba A. Brandes,

Neurology

2004

87

Page 1